

Cheleste M Thorpe

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5495134/cheleste-m-thorpe-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

17
papers

417
citations

9
h-index

18
g-index

18
ext. papers

530
ext. citations

4
avg, IF

3.66
L-index

| # | Paper | IF | Citations |
|----|--|------|-----------|
| 17 | Citrobacter rodentium(?Stx2dact), a murine infection model for enterohemorrhagic Escherichia coli.. <i>Current Opinion in Microbiology</i> , 2021 , 65, 183-190 | 7.9 | 0 |
| 16 | Ridinilazole, a narrow spectrum antibiotic for treatment of infection, enhances preservation of microbiota-dependent bile acids. <i>American Journal of Physiology - Renal Physiology</i> , 2020 , 319, G227-G237 | 5.1 | 7 |
| 15 | Impact of Body Mass Index (BMI) on the Effect of a Lactobacillus Rhamnosus GG (LGG)/Bifidobacterium Animalis Subspecies Lactis BB-12 (BB-12) Combination on Gut Microbiota (P20-023-19). <i>Current Developments in Nutrition</i> , 2019 , 3, | 0.4 | 78 |
| 14 | A repeat offender: Recurrent extraintestinal Clostridium difficile infection following fecal microbiota transplantation. <i>Anaerobe</i> , 2018 , 51, 68-72 | 2.8 | 5 |
| 13 | Antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from a Phase 2 clinical trial of ridinilazole (SMT19969) and vancomycin. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 2078-2084 | 5.1 | 9 |
| 12 | Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin. <i>PLoS ONE</i> , 2018 , 13, e0199810 | 3.7 | 26 |
| 11 | Epidemiologic Trends in Clostridium difficile Isolate Ribotypes in United States from 2010 to 2014. <i>Open Forum Infectious Diseases</i> , 2017 , 4, S391-S391 | 1 | 4 |
| 10 | Activation of the Classical Mitogen-Activated Protein Kinases Is Part of the Shiga Toxin-Induced Ribotoxic Stress Response and May Contribute to Shiga Toxin-Induced Inflammation. <i>Infection and Immunity</i> , 2016 , 84, 138-48 | 3.7 | 10 |
| 9 | A Novel Zak Knockout Mouse with a Defective Ribotoxic Stress Response. <i>Toxins</i> , 2016 , 8, | 4.9 | 6 |
| 8 | Effects of Shiga toxin type 2 on a bioengineered three-dimensional model of human renal tissue. <i>Infection and Immunity</i> , 2015 , 83, 28-38 | 3.7 | 17 |
| 7 | Effect of Lactobacillus rhamnosus GG Administration on Vancomycin-Resistant Enterococcus Colonization in Adults with Comorbidities. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 4593-9 | 5.9 | 28 |
| 6 | 1681Randomized Clinical Trial of the Recovery of Probiotics Lactobacillus rhamnosus GG (LGG) and Bifidobacterium animalis subspecies lactis (BB-12) from the Gastrointestinal (GI) Tract of Healthy Volunteers. <i>Open Forum Infectious Diseases</i> , 2014 , 1, S449-S449 | 1 | 78 |
| 5 | Foodborne illness: latest threats and emerging issues. Preface. <i>Infectious Disease Clinics of North America</i> , 2013 , 27, xiii-xiv | 6.5 | 2 |
| 4 | The role of Shiga toxin in promoting transepithelial migration of neutrophils. <i>FASEB Journal</i> , 2013 , 27, 131.9 | 0.9 | |
| 3 | Shiga toxin-producing Escherichia coli infection in South India. <i>Journal of Medical Microbiology</i> , 2009 , 58, 1525-1526 | 3.2 | 3 |
| 2 | Update on Clostridium difficile. <i>Current Treatment Options in Gastroenterology</i> , 2006 , 9, 265-71 | 2.5 | 16 |
| 1 | Shiga toxin-producing Escherichia coli infection. <i>Clinical Infectious Diseases</i> , 2004 , 38, 1298-303 | 11.6 | 128 |

